{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Conjunctivitis%2C+Allergic&page=2",
    "query": {
      "condition": "Conjunctivitis, Allergic",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Conjunctivitis%2C+Allergic&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T05:43:45.582Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06686472",
      "title": "Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "TL-925",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Telios Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2024-10-03",
      "completion_date": "2024-12-10",
      "has_results": false,
      "last_update_posted_date": "2024-11-13",
      "last_synced_at": "2026-06-26T05:43:45.582Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06686472"
    },
    {
      "nct_id": "NCT01685242",
      "title": "A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "AC-170 0.24%",
          "type": "DRUG"
        },
        {
          "name": "AC-170 0%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aciex Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2012-09",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2017-10-10",
      "last_synced_at": "2026-06-26T05:43:45.582Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01685242"
    },
    {
      "nct_id": "NCT02492321",
      "title": "A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Allergic Conjunctivitis (AC)"
      ],
      "interventions": [
        {
          "name": "EBI-005",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eleven Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2015-07",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2016-02-11",
      "last_synced_at": "2026-06-26T05:43:45.582Z",
      "location_count": 11,
      "location_summary": "Morrow, Georgia • Louisville, Kentucky • Andover, Massachusetts + 8 more",
      "locations": [
        {
          "city": "Morrow",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Quincy",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02492321"
    },
    {
      "nct_id": "NCT05591755",
      "title": "Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Seasonal Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Ketotifen fumarate ophthalmic solution 0.035%",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine tartrate ophthalmic solution 0.025%",
          "type": "DRUG"
        },
        {
          "name": "Experimental: Vehicle ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 229,
      "start_date": "2022-11-18",
      "completion_date": "2023-08-09",
      "has_results": true,
      "last_update_posted_date": "2025-07-01",
      "last_synced_at": "2026-06-26T05:43:45.582Z",
      "location_count": 6,
      "location_summary": "Louisville, Kentucky • Andover, Massachusetts • Goodlettsville, Tennessee + 3 more",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Goodlettsville",
          "state": "Tennessee"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Falls Church",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05591755"
    },
    {
      "nct_id": "NCT03038971",
      "title": "Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Allergic Conjunctivitis",
        "Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "Dose Level 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dose Level 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Woodmont Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "16 Years to 65 Years"
      },
      "enrollment_count": 2,
      "start_date": "2017-03-30",
      "completion_date": "2017-04-29",
      "has_results": false,
      "last_update_posted_date": "2018-02-26",
      "last_synced_at": "2026-06-26T05:43:45.582Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03038971"
    },
    {
      "nct_id": "NCT01443442",
      "title": "Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "bepotastine besilate, 1.5%",
          "type": "DRUG"
        },
        {
          "name": "Loteprednol etabonate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southern California College of Optometry at Marshall B. Ketchum University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2011-10",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2019-08-06",
      "last_synced_at": "2026-06-26T05:43:45.582Z",
      "location_count": 2,
      "location_summary": "Fullerton, California",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01443442"
    },
    {
      "nct_id": "NCT04050865",
      "title": "A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Dexamethasone, 0.4mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo plug with no drug",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Ocular Therapeutix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2019-08-05",
      "completion_date": "2020-02-28",
      "has_results": true,
      "last_update_posted_date": "2021-10-07",
      "last_synced_at": "2026-06-26T05:43:45.582Z",
      "location_count": 6,
      "location_summary": "Colorado Springs, Colorado • Louisville, Kentucky • Raynham, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Raynham",
          "state": "Massachusetts"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04050865"
    },
    {
      "nct_id": "NCT06602739",
      "title": "A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "REGN5713",
          "type": "DRUG"
        },
        {
          "name": "REGN5715",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2024-11-19",
      "completion_date": "2025-08-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-06-26T05:43:45.582Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06602739"
    },
    {
      "nct_id": "NCT01551056",
      "title": "A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "AC-170 0.24%",
          "type": "DRUG"
        },
        {
          "name": "AC-170 0%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aciex Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2012-03",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2017-11-07",
      "last_synced_at": "2026-06-26T05:43:45.582Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01551056"
    },
    {
      "nct_id": "NCT01120132",
      "title": "Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "CsA high dose",
          "type": "DRUG"
        },
        {
          "name": "CsA low dose",
          "type": "DRUG"
        },
        {
          "name": "PA",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fovea Pharmaceuticals SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 716,
      "start_date": "2010-05",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2012-03-09",
      "last_synced_at": "2026-06-26T05:43:45.582Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01120132"
    }
  ]
}